You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 3, March 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Public Health
 •Tobacco
 •Quality of Life
 •Rheumatology
 •Rheumatology, Other
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Drug Therapy, Other
 •Immunologic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Hypothalamic-Pituitary-Adrenal Axis Suppression in Systemic Glucocorticoid-Treated Infantile Hemangiomas

Putting the Risk Into Context

Robert Sidbury, MD, MPH

Arch Dermatol. 2009;145(3):319-320.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hemangiomas of infancy (IH) are the most common benign tumor of childhood.1 When small and located in nonvital areas, IH may be safely observed; however, approximately 10% to 20% become "problematic" and require intervention (Figure).2 The gold standard therapy is systemic glucocorticoids (GCs).3 Glucocorticoids have the following well-recognized adverse effects in infants4: irritability, gastrointestinal tract upset, appetite change, decreased growth while receiving treatment, fungal skin infection, hirsutism, cushingoid facies, hypertension, pneumocystis pneumonia, and hypothalamic-pituitary-adrenal (HPA) axis suppression, a potentially devastating adverse effect, which in the appropriate clinical setting may lead to adrenal crisis.


 
Figure appears in full text version.
Figure. Complications of infantile hemangiomas. *Typically in the setting of large liver hemangiomas and/or multiple cutaneous hemangiomas. {dagger}Kasabach-Merritt phenomenon, typically in the setting of proliferative vascular tumors of infancy other than infantile hemangiomas (eg, kaposiform hemangioendothelioma). {ddagger}Typically in the setting of a subglottic hemangioma often with cutaneous involvement in a . . . [Full Text of this Article]



AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Prevalence of Adrenal Insufficiency Following Systemic Glucocorticoid Therapy in Infants With Hemangiomas
Jefferson P. Lomenick, Kent L. Reifschneider, Anne W. Lucky, Denise Adams, Richard G. Azizkhan, Jessica G. Woo, and Philippe F. Backeljauw
Arch Dermatol. 2009;145(3):262-266.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.